To learn if routine symptom monitoring using questionnaires during chemotherapy and/or radiation therapy in patients with PDAC improves patient health-related quality of life and experience with care.
Age ≥18 years
Participants must have histologically confirmed PDAC that is respectable, borderline respectable, or locally advanced with potential for curative intent resection as defined by MD Anderson Cancer Center (Appendix V)
Participants must be eligible to receive systemic neoadjuvant therapy (chemotherapy +/- radiation therapy) with intent for curative resection
Participants who will receive neoadjuvant therapy at an MD Anderson facility including Texas Medical Center and Houston area locations
Definitively unresectable or metastatic disease at enrollment
Participants who received pre-referral chemotherapy, chemoradiotherapy, or previously attempted resection
Participants who had prior curative intent surgery for pancreatic cancer before entering the study
Participant with cognitive deficits that would preclude understanding of consent form and/or questionnaires
Single group
Standard of Care
Other interventionStandard of Care
safety and adverse events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
